Privigen 10% vial 400ML
Ended Awarded Last action
- Contract number
- SPE2DR26FDJP4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $21,573
Award facts
- Contract value 100% obligated
- $21,573.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $21,573.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of PRIVIGEN 10% vial 400ml. This firm fixed-price delivery order, issued on January 22, 2026, with an ultimate completion date of February 12, 2026, carries no set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
The PPV-G GEN V represents a $30.3 billion acquisition strategy through which the DLA establishes multiple regional prime vendor contractors to supply pharmaceutical products—including branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables—to support Department of Defense healthcare operations globally. DMS Pharmaceutical Group's product portfolio encompasses an extensive range of therapeutics and has demonstrated substantial federal contracting activity through numerous delivery orders, positioning the company as a critical supplier within the federal military medical supply chain. The contract structure enables the DLA to issue firm fixed-price delivery orders for recurring medical supply needs across military healthcare facilities worldwide, leveraging DMS Pharmaceutical Group's established performance record and specialized pharmaceutical distribution capabilities.
Quick answers
Who was awarded contract SPE2DR26FDJP4?
SPE2DR26FDJP4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FDJP4 worth?
The government has obligated $21,573 on SPE2DR26FDJP4.
Is contract SPE2DR26FDJP4 an order under another contract?
Yes. SPE2DR26FDJP4 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJP4 competed?
The extent of competition for SPE2DR26FDJP4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award